Integrating precision medicine in the study and clinical treatment of a severely mentally ill person

PeerJ

Volumn 2013, Issue 1, 2013, Pages

  O'Rawe, Jason A ^a,b   Fang, Han ^a,b   Rynearson, Shawn ^c   Robison, Reid ^d   Kiruluta, Edward S ^e   Higgins, Gerald ^f   Eilbeck, Karen ^c   Reese, Martin G ^e   Lyon, Gholson J ^a,b,d  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d Utah Foundation for Biomedical Research   (United States)

^e Omicia Inc   (United States)

^f AssureRx HealthInc   (United States)

Author keywords

Deep brain stimulation; Ethics; Genomics; Neurosurgery; Obsessive compulsive disorder; Whole genome sequencing

Indexed keywords

5, 10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CHOLINE ACETYLTRANSFERASE; CLOMIPRAMINE; FLUOXETINE; NERVE GROWTH FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN DEPTH STIMULATION; CAPSULA INTERNA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COPY NUMBER VARIATION; DEPRESSION; GENE SEQUENCE; GENETIC VARIABILITY; GENOMICS; HETEROZYGOTE; HUMAN; MALE; NUCLEUS ACCUMBENS; OBSESSIVE COMPULSIVE DISORDER; PARANOIA; PHARMACOGENETICS; PHENOTYPE; PSYCHOSIS; SCORING SYSTEM; SEXUAL DYSFUNCTION; TREATMENT OUTCOME;

EID: 84885086642     PISSN: None     EISSN: 21678359     Source Type: Journal    
DOI: 10.7717/peerj.177     Document Type: Article

References (108)

1. Alivisatos AP, Andrews AM, Boyden ES, Chun M, Church GM, Deisseroth K, Donoghue JP, Fraser SE, Lippincott-Schwartz J, Looger LL, Masmanidis S, McEuen PL, Nurmikko AV, Park H, Peterka DS, Reid C, Roukes ML, Scherer A, Schnitzer M, Sejnowski TJ, Shepard KL, Tsao D, Turrigiano G, Weiss PS, Xu C, Yuste R, Zhuang X. 2013a. Nanotools for neuroscience and brain activity mapping. ACS Nano 7:1850-1866 DOI 10.1021/nn4012847.
2. Alivisatos AP, Chun M, Church GM, Deisseroth K, Donoghue JP, Greenspan RJ, McEuen PL, Roukes ML, Sejnowski TJ, Weiss PS, Yuste R. 2013b. Neuroscience. The brain activity map. Science 339:1284-1285 DOI 10.1126/science.1236939.
3. Allen NC, Bagade S, McQueen MB, Ioannidis JPA, Kavvoura FK, Khoury MJ, Tanzi RE, Bertram L. 2008. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nature Genetics 40:827-834 DOI 10.1038/ng.171.
4. Alonso P, López-Solà C, Gratacós M, Fullana MA, Segalàs C, Real E, Cardoner N, Soriano-Mas C, Harrison BJ, Estivill X, Menchón JM. 2013. The interaction between Comt and Bdnf variants influences obsessive-compulsive-related dysfunctional beliefs. Journal of Anxiety Disorders 27:321-327 DOI 10.1016/j.janxdis.2013.02.012.
5. Alonso P, Segalàs C, Real E, Pertusa A, Labad J, Jiménez-Murcia S, Jaurrieta N, Bueno B, Vallejo J, Menchón JM. 2010. Suicide in patients treated for obsessive-compulsive disorder: A prospective follow-up study. Journal of Affective Disorders 124:300-308 DOI 10.1016/j.jad.2009.12.001.
6. Balci V, Sevincok L. 2010. Suicidal ideation in patients with obsessive-compulsive disorder. Psychiatry Research 175:104-108 DOI 10.1016/j.psychres.2009.03.012.
7. Biesecker BB, Peay HL. 2013. Genomic sequencing for psychiatric disorders: promise and challenge. The International Journal of Neuropsychopharmacology 16(7):1667-1672 DOI 10.1017/S146114571300014X.
8. Blomstedt P, Sjöberg RL, Hansson M, Bodlund O, Hariz MI. 2012. Deep brain stimulation in the treatment of obsessive-compulsive disorder. World Neurosurgery In Press DOI 10.1016/j.wneu.2012.10.006.
9. Bozok Cetintas V, Erer OF, Kosova B, Ozdemir I, Topcuoglu N, Aktogu S, Eroglu Z. 2008. Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests. Tüberküloz ve Toraks 56:81-86. Available at http://www.tuberktoraks.org/managete/fufolder/2008-01/2008-56-1-081-086.pdf.
10. Brown SH, Lincoln MJ, Groen PJ, Kolodner RM. 2003. VistA-US Department of Veterans Affairs national-scale HIS. International Journal of Medical Informatics 69:135-156 DOI 10.1016/S1386-5056(02)00131-4.
11. Burdick AP, Foote KD. 2011. Advancing deep brain stimulation for obsessive-compulsive disorder. Expert Review of Neurotherapeutics 11:341-344 DOI 10.1586/ern.11.20.
12. Burdick A, Goodman WK, Foote KD. 2009. Deep brain stimulation for refractory obsessive-compulsive disorder. Frontiers in Bioscience 14:1880-1890 DOI 10.2741/3348.
13. Collip D, vanWinkel R, Peerbooms O, Lataster T, Thewissen V, Lardinois M, Drukker M, Rutten BPF, Van Os J, Myin-Germeys I. 2011. COMT Val158Met-stress interaction in psychosis: role of background psychosis risk. CNS Neuroscience & Therapeutics 17:612-619 DOI 10.1111/j.1755-5949.2010.00213.x.
14. Conn J. 2011. VA to update VistA EHR. Modern Healthcare 41:17.
15. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. 2009. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765-1773 DOI 10.1001/jama.2009.1549.
16. Davis M. 1992. The role of the amygdala in fear and anxiety. Annual Review of Neuroscience 15:353-375 DOI 10.1146/annurev.ne.15.030192.002033.
17. Denys D, Mantione M. 2009. Deep brain stimulation in obsessive-compulsive disorder. Progress in Brain Research 175:419-427 DOI 10.1016/S0079-6123(09)17527-1.
18. Denys D, Mantione M, Figee M, van denMunckhof P, Koerselman F, Westenberg H, Bosch A, Schuurman R. 2010. Deep brain stimulation of the nucleus accumbens for treatment-refractory obsessive-compulsive disorder. Archives of General Psychiatry 67:1061-1068 DOI 10.1001/archgenpsychiatry.2010.122.
19. Dumontheil I, Roggeman C, Ziermans T, Peyrard-Janvid M, Matsson H, Kere J, Klingberg T. 2011. Influence of the COMT genotype on working memory and brain activity changes during development. Biological Psychiatry 70:222-229 DOI 10.1016/j.biopsych.2011.02.027.
20. Eichenbaum H. 2013. What H.M. taught us. Journal of Cognitive Neuroscience 25:14-21 DOI 10.1162/jocn a 00285.
21. Eilbeck K. 2013. Genome Variation Format (Clinical). Available at http://www.sequenceontology.org/resources/gvfclin.html.
22. Erickson-Davis C. 2012. Ethical concerns regarding commercialization of deep brain stimulation for obsessive compulsive disorder. Bioethics 26:440-446 DOI 10.1111/j.1467-8519.2011.01886.x.
23. Figee M, Luigjes J, Smolders R, Valencia-Alfonso C-E, vanWingen G, de Kwaasteniet B, Mantione M, Ooms P, de Koning P, Vulink N, Levar N, Droge L, van denMunckhof P, Schuurman PR, Nederveen A, van den Brink W, Mazaheri A, Vink M, Denys D. 2013. Deep brain stimulation restores frontostriatal network activity in obsessive-compulsive disorder. Nature Neuroscience 16:386-387 DOI 10.1038/nn.3344.
24. Fins JJ. 2010. Deep brain stimulation, free markets and the scientific commons: is it time to revisit the Bayh-Dole act of 1980? Neuromodulation 13:153-159 DOI 10.1111/j.1525-1403.2009.00238.x.
25. Fins JJ, Dorfman GS, Pancrazio JJ. 2012. Challenges to deep brain stimulation: a pragmatic response to ethical, fiscal, and regulatory concerns. Annals of the New York Academy of Sciences 1265:80-90 DOI 10.1111/j.1749-6632.2012.06598.x.
26. Fins JJ, Mayberg HS, Nuttin B, Kubu CS, Galert T, SturmV, Stoppenbrink K, Merkel R, Schlaepfer TE. 2011a. Misuse of the FDA's humanitarian device exemption in deep brain stimulation for obsessive-compulsive disorder. Health Affairs 30:302-311 DOI 10.1377/hlthaff.2010.0157.
27. Fins JJ, Schlaepfer TE, Nuttin B, Kubu CS, Galert T, SturmV, Merkel R, Mayberg HS. 2011b. Ethical guidance for the management of conflicts of interest for researchers, engineers and clinicians engaged in the development of therapeutic deep brain stimulation. Journal of Neural Engineering 8:033001 DOI 10.1088/1741-2560/8/3/033001.
28. Fins JJ, SchiffND. 2010. Conflicts of interest in deep brain stimulation research and the ethics of transparency. Journal of Clinical Ethics 21:125-132.
29. Frayling TM. 2008. Commentary: genetic association studies see light at the end of the tunnel. International Journal of Epidemiology 37:133-135 DOI 10.1093/ije/dym205.
30. Friend SF, Peterson LK, Kedl RM, Dragone LL. 2013. SLAP deficiency increases TCR avidity leading to altered repertoire and negative selection of cognate antigen-specific CD8C T cells. Immunologic Research 55:116-124 DOI 10.1007/s12026-012-8354-y.
31. Gillihan SJ, Williams MT, Malcoun E, Yadin E, Foa EB. 2012. Common pitfalls in exposure and response prevention (EX/RP) for OCD. Journal of Obsessive-Compulsive and Related Disorders 1:251-257 DOI 10.1016/j.jocrd.2012.05.002.
32. Goodman WK, Alterman RL. 2012. Deep brain stimulation for intractable psychiatric disorders. Annual Review of Medicine 63:511-524 DOI 10.1146/annurev-med-052209-100401.
33. Goodman WK, Foote KD, Greenberg BD, Ricciuti N, Bauer R, Ward H, Shapira NA, Wu SS, Hill CL, Rasmussen SA, Okun MS. 2010. Deep brain stimulation for intractable obsessive compulsive disorder: pilot study using a blinded, staggered-onset design. Biological Psychiatry 67:535-542 DOI 10.1016/j.biopsych.2009.11.028.
34. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS. 1989a. The Yale-Brown obsessive compulsive scale. I. Development, use, and reliability. Archives of General Psychiatry 46:1006-1011 DOI 10.1001/archpsyc. 1989.01810110048007.
35. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS. 1989b. The Yale-Brown obsessive compulsive scale. II. Validity. Archives of General Psychiatry 46:1012-1016 DOI 10.1001/archpsyc.1989.01810110054008.
36. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, McGuire A, Nussbaum RL, O'Daniel JM, Ormond KE, Rehm HL, Watson MS, Williams MS, Biesecker LG. 2013. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Available at https://www.acmg.net/docs/ACMGReleasesHighly-AnticipatedRecommendationsonIncidentalFindingsinClinicalExomeandGenomeSequencing.pdf.
37. Greenberg B. 2013. Effectiveness of deep brain stimulation for treating people with treatment resistant obsessive-compulsive disorder. In: ClinicalTrials.gov. Bethesda: National Library of Medicine. NCT00640133. Available at http://clinicaltrials.gov/show/NCT00640133.
38. Greenberg BD, Malone DA, Friehs GM, Rezai AR, Kubu CS, Malloy PF, Salloway SP, Okun MS, Goodman WK, Rasmussen SA. 2006. Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology 31:2384-2393 DOI 10.1038/sj.npp.1301165.
39. Hall D, Dhilla A, Charalambous A, Gogos JA, Karayiorgou M. 2003. Sequence variants of the brain-derived neurotrophic factor (BDNF) gene are strongly associated with obsessive-compulsive disorder. The American Journal of Human Genetics 73:370-376 DOI 10.1086/377003.
40. Haynes WIA, Mallet L. 2010. High-frequency stimulation of deep brain structures in obsessive-compulsive disorder: the search for a valid circuit. European Journal of Neuroscience 32:1118-1127 DOI 10.1111/j.1460-9568.2010.07418.x.
41. Höflich A, Savli M, Comasco E, Moser U, Novak K, Kasper S, Lanzenberger R. 2013. Neuropsychiatric deep brain stimulation for translational neuroimaging. NeuroImage 79:30-41 DOI 10.1016/j.neuroimage.2013.04.065.
42. Individual Genome Sequencing (IGS) Test. 2013. Available at http://www.illumina.com/clinical/illuminaclinicallaboratory.ilmn.
43. Ira E, Zanoni M, Ruggeri M, Dazzan P, Tosato S. 2013. COMT, neuropsychological function and brain structure in schizophrenia: a systematic review and neurobiological interpretation. Journal of Psychiatry and Neuroscience 38:120178.
44. Jiménez-Ponce F, Velasco-Campos F, Castro-Farfán G, Nicolini H, Velasco AL, Salín-Pascual R, Trejo D, Criales JL. 2009. Preliminary study in patients with obsessive-compulsive disorder treated with electrical stimulation in the inferior thalamic peduncle. Neurosurgery 65:203-209 DOI 10.1227/01.NEU.0000345938.39199.90.
45. Johnson MR, Wang K, Tillmanns S, Albin N, Diasio RB. 1997. Structural organization of the human dihydropyrimidine dehydrogenase gene. Cancer Research 57:1660-1663.
46. Kim TI, McCall JG, Jung YH, Huang X, Siuda ER, Li Y, Song J, Song YM, Pao HA, Kim R-H, Lu C, Lee SD, Song I-S, Shin G, Al-Hasani R, Kim S, Tan MP, Huang Y, Omenetto FG, Rogers JA, Bruchas MR. 2013. Injectable, cellular-scale optoelectronics with applications for wireless optogenetics. Science 340:211-216 DOI 10.1126/science.1232437.
47. Klei L, Sanders SJ, Murtha MT, Hus V, Lowe JK, Willsey AJ, Moreno-De-Luca D, Yu TW, Fombonne E, Geschwind D, Grice DE, Ledbetter DH, Lord C, Mane SM, LeseMartin C, Martin DM, Morrow EM, Walsh CA, MelhemNM, Chaste P, Sutcliffe JS, State MW, Cook EH Jr, Roeder K, Devlin B. 2012. Common genetic variants, acting additively, are a major source of risk for autism. Molecular Autism 3:9 DOI 10.1186/2040-2392-3-9.
48. Komotar RJ, Hanft SJ, Connolly ES Jr. 2009. Deep brain stimulation for obsessive compulsive disorder. Neurosurgery 64:N13 DOI 10.1227/01.NEU.0000349645.64376.86.
49. Kuzmak PM, DayhoffRE. 1998. The Department of Veterans Affairs integration of imaging into the healthcare enterprise using the VistA hospital information system and Digital Imaging and Communications in Medicine. Journal of Digital Imaging 11:53-64 DOI 10.1007/BF03168727.
50. Lajin B, Alachkar A, Hamzeh AR, Michati R, Alhaj H. 2011. No association between Val158Met of the COMT gene and susceptibility to schizophrenia in the Syrian population. North American Journal of Medical Sciences 3:176-178 DOI 10.4297/najms.2011.3176.
51. Lau JYF, Goldman D, Buzas B, Hodgkinson C, Leibenluft E, Nelson E, Sankin L, Pine DS, Ernst M. 2010. BDNF gene polymorphism (Val66Met) predicts amygdala and anterior hippocampus responses to emotional faces in anxious and depressed adolescents. NeuroImage 53:952-961 DOI 10.1016/j.neuroimage.2009.11.026.
52. Lipsman N, Gerretsen P, Torres C, Lozano AM, Giacobbe P. 2012. A psychiatric primer for the functional neurosurgeon. Journal of Neurosurgical Sciences 56:209-220.
53. Lipsman N, Neimat JS, Lozano AM. 2007. Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: the search for a valid target. Neurosurgery 61:1-11; discussion 11-13 DOI 10.1227/01.neu.0000279719.75403.f7.
54. Lopez-Garcia P, Young Espinoza L, Molero Santos P, Marin J, Ortu~no Sanchez-Pedreño F. 2012. Impact of COMT genotype on cognition in schizophrenia spectrum patients and their relatives. Psychiatry Research DOI 10.1016/j.psychres.2012.09.043.
55. Lundblad MS, Stark K, Eliasson E, Oliw E, Rane A. 2005. Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes. Biochemical and Biophysical Research Communications 327:1052-1057 DOI 10.1016/j.bbrc.2004.12.116.
56. Luria AR. 1972. The man with a shattered world: the history of a brain wound. In: Basic books. Cambridge: Harvard University Press.
57. Luria AR. 1976. The mind of a mnemonist: a little book about a vast memory. In: H. Regnery. Cambridge: Harvard University Press.
58. Lyon GJ. 2012a. Guest post: time to bring human genome sequencing into the clinic. Available at http://www.genomesunzipped.org/2012/02/guest-post-time-to-bring-human-genome-sequencinginto-the-clinic.php.
59. Lyon GJ. 2012b. Personalized medicine: bring clinical standards to human-genetics research. Nature 482:300-301 DOI 10.1038/482300a.
60. Lyon GJ. 2012c. There is nothing "incidental" about unrelated findings. Personalized Medicine 9:163-166 DOI 10.2217/pme.11.98.
61. Lyon GJ, Segal JP. 2013. Practical, ethical and regulatory considerations for the evolving medical and research genomics landscape. Applied & Translational Genomics In Press DOI 10.1016/j.atg.2013.02.001.
62. Lyon GJ, Wang K. 2012. Identifying disease mutations in genomic medicine settings: current challenges and how to accelerate progress. Genome Medicine 4:58 DOI 10.1186/gm359.
63. Maina G, Rosso G, Zanardini R, Bogetto F, Gennarelli M, Bocchio-Chiavetto L. 2010. Serum levels of brain-derived neurotrophic factor in drug-naive obsessive-compulsive patients: a case-control study. Journal of Affective Disorders 122:174-178 DOI 10.1016/j.jad.2009.07.009.
64. Mancama D, Mata I, Kerwin RW, Arranz MJ. 2007. Choline acetyltransferase variants and their influence in schizophrenia and olanzapine response. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 144B:849-853 DOI 10.1002/ajmg.b.30468.
65. Medtronic. 2013. Getting DBS therapy for OCD. Available at http://www.medtronic.com/patients/obsessive-compulsive-disorder-ocd/getting-therapy/.
66. Mian MK, Campos M, Sheth SA, Eskandar EN. 2010. Deep brain stimulation for obsessive-compulsive disorder: past, present, and future. Neurosurgical Focus 29:E10 DOI 10.3171/2010.4.FOCUS10107.
67. Mitchell KJ. 2012. What is complex about complex disorders? Genome Biology 13:237 DOI 10.1186/gb-2012-13-1-237.
68. Mitchell KJ, Porteous DJ. 2011. Rethinking the genetic architecture of schizophrenia. Psychological Medicine 41:19-32 DOI 10.1017/S003329171000070X.
69. Montag C, Reuter M, Newport B, Elger C, Weber B. 2008. The BDNF Val66Met polymorphism affects amygdala activity in response to emotional stimuli: evidence from a genetic imaging study. NeuroImage 42:1554-1559 DOI 10.1016/j.neuroimage.2008.06.008.
70. Moreno-De-Luca A, Myers SM, Challman TD, Moreno-De-Luca D, Evans DW, Ledbetter DH. 2013. Developmental brain dysfunction: revival and expansion of old concepts based on new genetic evidence. The Lancet Neurology 12:406-414 DOI 10.1016/S1474-4422(13)70011-5.
71. Moscarello JM, LeDoux JE. 2013. Active avoidance learning requires prefrontal suppression of amygdala-mediated defensive reactions. The Journal of Neuroscience 33:3815-3823 DOI 10.1523/JNEUROSCI.2596-12.2013.
72. Murphy TW, Zine EE, Jenike MA. 2009. Life in rewind: the story of a young courageous man who persevered over OCD and the Harvard doctor who broke all the rules to help him, 1st edn. New York: William Morrow.
73. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW. 2004. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics and Genomics 14:1-18 DOI 10.1097/00008571-200401000-00001.
74. Nicolelis MAL. 2012. Mind in motion. Scientific American 307:58-63 DOI 10.1038/scientificamerican0912-58.
75. Nielsen R, Paul JS, Albrechtsen A, Song YS. 2011. Genotype and SNP calling from next-generation sequencing data. Nature Reviews Genetics 12:443-451 DOI 10.1038/nrg2986.
76. Omicia. 2013. Available at http://www.omicia.com/
77. O'Rawe J, Jiang T, Sun G, Wu Y, Wang W, Hu J, Bodily P, Tian L, Hakonarson H, Johnson WE, Wei Z, Wang K, Lyon GJ. 2013. Low concordance of multiple variant-calling pipelines: practical implications for exome and genome sequencing. Genome Medicine 5:28 DOI 10.1186/gm432.
78. Pais-Vieira M, Lebedev M, Kunicki C, Wang J, Nicolelis MA. 2013. A brain-to-brain interface for real-time sharing of sensorimotor information. Scientific Reports 3:1319 DOI 10.1038/srep01319.
79. Pigott TA, Pato MT, Bernstein SE, Grover GN, Hill JL, Tolliver TJ, Murphy DL. 1990. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results. Archives of General Psychiatry 47:926-932 DOI 10.1001/archpsyc.1990.01810220042005.
80. Pigott TA, Seay SM. 1999. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. Journal of Clinical Psychiatry 60:101-106 DOI 10.4088/JCP.v60n0206.
81. Protti D, Groen P. 2008. Implementation of the Veterans Health Administration VistA clinical information system around the world. Healthcare Quarterly 11:83-89.
82. Ratiu P, Talos I-F, Haker S, Lieberman D, Everett P. 2004. The tale of Phineas Gage, digitally remastered. Journal of Neurotrauma 21:637-643 DOI 10.1089/089771504774129964.
83. Raznahan A, Greenstein D, Lee Y, Long R, Clasen L, Gochman P, Addington A, Giedd JN, Rapoport JL, Gogtay N. 2011. Catechol-o-methyl transferase (COMT) val158met polymorphism and adolescent cortical development in patients with childhood-onset schizophrenia, their non-psychotic siblings, and healthy controls. NeuroImage 57:1517-1523 DOI 10.1016/j.neuroimage.2011.05.032.
84. Reese MG, Moore B, Batchelor C, Salas F, Cunningham F, Marth GT, Stein L, Flicek P, Yandell M, Eilbeck K. 2010. A standard variation file format for human genome sequences. Genome Biology 11:R88 DOI 10.1186/gb-2010-11-8-r88.
85. Ring BJ, Eckstein JA, Gillespie JS, Binkley SN, VandenBranden M, Wrighton SA. 2001. Identification of the human cytochromes p450 responsible for in vitro formation of R- and S-norfluoxetine. Journal of Pharmacology and Experimental Therapeutics 297:1044-1050.
86. Rodriguez-Romaguera J, DoMonte FH, Quirk GJ. 2012. Deep brain stimulation of the ventral striatum enhances extinction of conditioned fear. Proceedings of the National Academy of Sciences of the United States of America 109:8764-8769 DOI 10.1073/pnas.1200782109.
87. Roffman JL, Gollub RL, Calhoun VD, Wassink TH, Weiss AP, Ho BC, White T, Clark VP, Fries J, Andreasen NC, GoffDC, Manoach DS. 2008. MTHFR 677C ! T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val ! Met. Proceedings of the National Academy of Sciences of the United States of America 105:17573-17578 DOI 10.1073/pnas.0803727105
88. Roh D, ChangWS, Chang JW, Kim C-H. 2012. Long-term follow-up of deep brain stimulation for refractory obsessive-compulsive disorder. Psychiatry Research 200:1067-1070 DOI 10.1016/j.psychres.2012.06.018.
89. Rosa A, Cuesta MJ, Fatjó-Vilas M, Peralta V, Zarzuela A, Fañanás L. 2006. The Val66Met polymorphism of the brain-derived neurotrophic factor gene is associated with risk for psychosis: evidence from a family-based association study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 141B:135-138 DOI 10.1002/ajmg.b.30266.
90. Sacco JC, Abouraya M, Motsinger-Reif A, Yale SH, McCarty CA, Trepanier LA. 2012. Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivity. Pharmacogenetics and Genomics 22:733-740 DOI 10.1097/FPC.0b013e328357a735.
91. Sacks OW. 1995. An anthropologist on Mars: seven paradoxical tales. Vintage.
92. Sacks OW. 1998. The man who mistook his wife for a hat and other clinical tales. Simon & Schuster.
93. Shah DB, Pesiridou A, Baltuch GH, Malone DA, O'Reardon JP. 2008. Functional neurosurgery in the treatment of severe obsessive compulsive disorder and major depression: overview of disease circuits and therapeutic targeting for the clinician. Psychiatry (Edgmont) 5:24-33.
94. Shestopal SA, Johnson MR, Diasio RB. 2000. Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression 1494:162-169 DOI 10.1016/S0167-4781(00)00213-X.
95. Sim SC, Ingelman-Sundberg M. 2013. Update on allele nomenclature for human cytochromes P450 and the Human Cytochrome P450 Allele (CYP-allele) Nomenclature Database. Methods in Molecular Biology 987:251-259 DOI 10.1007/978-1-62703-321-3 21.
96. Singh JP, Volavka J, Czobor P, Van Dorn RA. 2012. A meta-analysis of the Val158Met COMT polymorphism and violent behavior in schizophrenia. PLoS ONE 7:e43423 DOI 10.1371/journal.pone.0043423.
97. Soliman F, Glatt CE, Bath KG, Levita L, Jones RM, Pattwell SS, Jing D, Tottenham N, Amso D, Somerville LH, Voss HU, Glover G, Ballon DJ, Liston C, Teslovich T, Van Kempen T, Lee FS, Casey BJ. 2010. A genetic variant BDNF polymorphism alters extinction learning in both mouse and human. Science 327:863-866 DOI 10.1126/science.1181886.
98. Strata Conference. 2013. Support the proposed federal rule to expand the rights of patients to access their test results. Available at http://strataconf.com/rx2012/public/content/consensus.
99. Synofzik M, Fins JJ, Schlaepfer TE. 2012. A neuromodulation experience registry for deep brain stimulation studies in psychiatric research: rationale and recommendations for implementation. Brain Stimulation 5:653-655 DOI 10.1016/j.brs.2011.10.003.
100. Thomson EE, Carra R, Nicolelis MAL. 2013. Perceiving invisible light through a somatosensory cortical prosthesis. Nature Communications 4:1482 DOI 10.1038/ncomms2497.
101. Torres AR, Ramos-Cerqueira ATA, Ferrao YA, Fontenelle LF, do Rosário MC, Miguel EC. 2011. Suicidality in obsessive-compulsive disorder: prevalence and relation to symptom dimensions and comorbid conditions [CME]. The Journal of Clinical Psychiatry 72:17-26 DOI 10.4088/JCP.09m05651blu.
102. Van Horn JD, Irimia A, Torgerson CM, Chambers MC, Kikinis R, Toga AW. 2012. Mapping connectivity damage in the case of Phineas Gage. PLoS ONE 7:e37454 DOI 10.1371/journal.pone.0037454.
103. vanWinkel R, Moons T, Peerbooms O, Rutten B, Peuskens J, Claes S, van Os J, De Hert M. 2010. MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study. International Clinical Psychopharmacology 25:270-276 DOI 10.1097/YIC.0b013e32833bc60d.
104. Visscher PM, Goddard ME, Derks EM, Wray NR. 2011. Evidence-based psychiatric genetics, AKA the false dichotomy between common and rare variant hypotheses. Molecular Psychiatry DOI 10.1038/mp.2011.65.
105. Worthey EA, Mayer AN, Syverson GD, Helbling D, Bonacci BB, Decker B, Serpe JM, Dasu T, Tschannen MR, Veith RL, Basehore MJ, Broeckel U, Tomita-Mitchell A, Arca MJ, Casper JT, Margolis DA, Bick DP, Hessner MJ, Routes JM, Verbsky JW, Jacob HJ, Dimmock DP. 2011. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genetics in Medicine 13:255-262 DOI 10.1097/GIM.0b013e3182088158.
106. Yu J-H, Jamal SM, Tabor HK, Bamshad MJ. 2013. Self-guided management of exome and whole-genome sequencing results: changing the results return model. Genetics in Medicine 15:684-690 DOI 10.1038/gim.2013.35.
107. Zhou S-F, Liu J-P, Chowbay B. 2009. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metabolism Reviews 41:89-295 DOI 10.1080/03602530902843483.
108. Zhu M, Need AC, Han Y, Ge D, Maia JM, Zhu Q, Heinzen EL, Cirulli ET, Pelak K, He M, Ruzzo EK, Gumbs C, Singh A, Feng S, Shianna KV, Goldstein DB. 2012. Using ERDS to infer copy-number variants in high-coverage genomes. The American Journal of Human Genetics 91:408-421 DOI 10.1016/j.ajhg.2012.07.004.